Genome-Scale CRISPR Screening in Human Intestinal Organoids Identifies Drivers of TGF-β Resistance.


Journal

Cell stem cell
ISSN: 1875-9777
Titre abrégé: Cell Stem Cell
Pays: United States
ID NLM: 101311472

Informations de publication

Date de publication:
05 03 2020
Historique:
received: 22 10 2018
revised: 30 07 2019
accepted: 13 02 2020
entrez: 7 3 2020
pubmed: 7 3 2020
medline: 28 4 2021
Statut: ppublish

Résumé

Forward genetic screens with genome-wide CRISPR libraries are powerful tools for resolving cellular circuits and signaling pathways. Applying this technology to organoids, however, has been hampered by technical limitations. Here we report improved accuracy and robustness for pooled-library CRISPR screens by capturing sgRNA integrations in single organoids, substantially reducing required cell numbers for genome-scale screening. We applied our approach to wild-type and APC mutant human intestinal organoids to identify genes involved in resistance to TGF-β-mediated growth restriction, a key process during colorectal cancer progression, and validated hits including multiple subunits of the tumor-suppressive SWI/SNF chromatin remodeling complex. Mutations within these genes require concurrent inactivation of APC to promote TGF-β resistance and attenuate TGF-β target gene transcription. Our approach can be applied to a variety of assays and organoid types to facilitate biological discovery in primary 3D tissue models.

Identifiants

pubmed: 32142663
pii: S1934-5909(20)30060-6
doi: 10.1016/j.stem.2020.02.007
pii:
doi:

Substances chimiques

Transforming Growth Factor beta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

431-440.e8

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests H.C. is an inventor on applications/patents related to organoid technology. The other authors declare no competing interests.

Auteurs

Till Ringel (T)

Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland; Department of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.

Nina Frey (N)

Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.

Femke Ringnalda (F)

Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.

Sharan Janjuha (S)

Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland; Department of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.

Sarah Cherkaoui (S)

Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.

Stefan Butz (S)

Department of Molecular Mechanisms of Disease, University of Zurich, Zurich, Switzerland.

Sumana Srivatsa (S)

Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland.

Martin Pirkl (M)

Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland.

Giancarlo Russo (G)

Functional Genomics Center Zurich, University of Zurich, ETH Zurich, Zurich, Switzerland.

Lukas Villiger (L)

Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.

Gerhard Rogler (G)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Hans Clevers (H)

University Medical Center (UMC) Utrecht, Utrecht, the Netherlands; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, the Netherlands.

Niko Beerenwinkel (N)

Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland.

Nicola Zamboni (N)

Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.

Tuncay Baubec (T)

Department of Molecular Mechanisms of Disease, University of Zurich, Zurich, Switzerland.

Gerald Schwank (G)

Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland; Department of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. Electronic address: schwank@pharma.uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH